X4 Pharmaceuticals, Inc. (XFOR)
4.04
-0.19
(-4.49%)
USD |
NASDAQ |
Aug 28, 16:00
4.12
+0.08
(+1.98%)
After-Hours: 20:00
X4 Pharmaceuticals Free Cash Flow : -88.74M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -88.74M |
| March 31, 2026 | -92.85M |
| December 31, 2025 | -88.62M |
| September 30, 2025 | -106.13M |
| June 30, 2025 | -112.43M |
| March 31, 2025 | -112.94M |
| December 31, 2024 | -131.23M |
| September 30, 2024 | -125.97M |
| June 30, 2024 | -112.68M |
| March 31, 2024 | -103.71M |
| December 31, 2023 | -96.57M |
| September 30, 2023 | -87.92M |
| June 30, 2023 | -86.40M |
| March 31, 2023 | -83.48M |
| December 31, 2022 | -77.20M |
| September 30, 2022 | -77.14M |
| June 30, 2022 | -72.06M |
| March 31, 2022 | -72.83M |
| December 31, 2021 | -71.52M |
| September 30, 2021 | -70.26M |
| Date | Value |
|---|---|
| June 30, 2021 | -70.85M |
| March 31, 2021 | -63.04M |
| December 31, 2020 | -60.18M |
| September 30, 2020 | -51.70M |
| June 30, 2020 | -49.73M |
| March 31, 2020 | -51.83M |
| December 31, 2019 | -48.06M |
| September 30, 2019 | -45.55M |
| June 30, 2019 | -39.50M |
| March 31, 2019 | -30.99M |
| December 31, 2018 | -25.42M |
| September 30, 2018 | -31.58M |
| June 30, 2018 | -29.96M |
| March 31, 2018 | -30.57M |
| December 31, 2017 | -27.91M |
| September 30, 2017 | -18.19M |
| June 30, 2017 | -31.51M |
| March 31, 2017 | -19.10M |
| December 31, 2016 | -21.64M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Sarepta Therapeutics, Inc. | 58.34M |
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Anixa Biosciences, Inc. | -7.117M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -20.79M |
| Cash from Investing (Quarterly) | -1.00M |
| Cash from Financing (Quarterly) | 0.075M |
| Free Cash Flow Per Share (Quarterly) | -0.2041 |
| Free Cash Flow to Equity (Quarterly) | -25.76M |
| Free Cash Flow to Firm (Quarterly) | -23.62M |
| Free Cash Flow Yield | -21.62% |